Janssen Risperdal for bipolar mania
Executive Summary
Janssen's Risperdal (risperidone) approved Dec. 4 for short-term treatment of bipolar mania, as monotherapy or in combination with lithium or valproate. J&J has committed to a long-term bipolar mania study as post-marketing commitment. Updated labeling adds diabetes class warning, removes warnings on QT prolongation. Lilly's Zyprexa (olanzapine) was the first atypical with a short-term bipolar mania indication; Zyprexa is "approvable" for bipolar maintenance (1"The Pink Sheet" Nov. 3, 2003, p. 26)...
You may also be interested in...
Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates
Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...
Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.
Moderna COVID-19 Boosters Show Preclinical Efficacy Versus South African Variant
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.